The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Domino’s Weighs Appeal After Australian Court Rules Workers Were Misled on Pay 
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Brazil Court Bars Flavio Bolsonaro From Visiting Jair Bolsonaro Ahead of Election 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Macquarie Names Greg Ward as CEO, Signaling Stability and Strategic Continuity 
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
Nike Shifts China Online Sales Strategy to Boost Brand and Fight Local Rivals 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
Trump ICC Sanctions Challenged as Advocacy Groups File Free Speech Lawsuit 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Two major pharmaceutical companies, Danco Laboratories and GenBioPro, have petitioned the U.S. Supreme Court to restore nationwide mail-order access to mifepristone, a widely used abortion pill. The emergency request comes after a federal appeals court temporarily blocked remote distribution of the drug, creating uncertainty for patients and healthcare providers across the United States.
The ruling from the 5th U.S. Circuit Court of Appeals in New Orleans significantly limits access to mifepristone, particularly affecting women in states with strict abortion bans. This decision marks a critical moment in ongoing legal battles over reproductive healthcare, especially following the 2022 Supreme Court decision that overturned Roe v. Wade. Since then, many states have imposed severe abortion restrictions, increasing reliance on medication abortion as an alternative.
Mifepristone, used in combination with misoprostol, accounts for roughly two-thirds of all abortions in the U.S. and is approved for use during the first 10 weeks of pregnancy. In 2023, the U.S. Food and Drug Administration (FDA) removed the requirement for in-person dispensing, allowing telehealth prescriptions and mail delivery after determining the drug is safe and effective.
However, Louisiana and other Republican-led states have challenged the FDA’s regulatory authority, citing potential health risks such as severe bleeding and infection. The appeals court sided with Louisiana, stating the state is likely to succeed in its legal challenge, prompting immediate action from drug manufacturers.
Danco warned that the decision creates confusion for patients and providers, disrupting time-sensitive medical care. GenBioPro emphasized the importance of maintaining access to safe, evidence-based healthcare and raised concerns about political interference in FDA oversight.
The Supreme Court previously declined a similar case in 2024 due to lack of legal standing, but new challenges led by states including Missouri, Kansas, and Idaho are still pending. As legal battles intensify, the outcome of this case could have far-reaching implications for abortion access and pharmaceutical regulation in the U.S.
